Viatris Wins First US Symbicort Generic – Will It Launch At Risk?
Federal Circuit Recently Told AstraZeneca It Would Not Review Viatris Win
In the wake of a favorable US Court of Appeals for the Federal Circuit decision, Viatris has won FDA approval for the first generic Symbicort product. The ANDA sponsor’s management had recently declared itself “ready to launch if the opportunity presents itself in 2022.”
You may also be interested in...
Viatris has persuaded a US district court that a further patent shielding AstraZeneca’s Symbicort pressurized metered dose inhaler is invalid. The ANDA sponsor, holding the only US FDA approval for a generic version of the blockbuster, has the potential to launch – although a further trial is planned in December.
Facing down a key patent infringement trial beginning on 19 May, Viatris is continuing to eye an opportunity to launch its Breyna generic version of AstraZeneca’s Symbicort before patent expiry in 2023.
In drug pricing move, Public Citizen and others petition HHS Secretary Becerra to use government authorities to get generic versions of six drugs on the market before patent expiration.